Texas is currently home to 4848 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
BIOlogic Augmented Repair of Complex Anal Fistula Using Acellular Matrix and/or Autologous Platelet-rich Plasma
NCT05805449
Recruiting
The purpose of this study is to compare the clinical effectiveness of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix (UBM) to usual surgical care alone to prevent fistula recurrence or improve HRQoL, to compare the effects of augmenting surgical repair of complex anal fistula using autologous PRP and/or micronized acellular porcine urinary bladder matrix on early postoperative pain and fecal continence and to ass... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Anal Fistula
Register for Updates
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04921345
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 2 years and 12 years
Trial Updated:
04/05/2023
Locations: Galderma Investigational Site #9931, Beaumont, Texas
Conditions: Moderate-to-Severe Atopic Dermatitis
Register for Updates
IHT for Mild Cognitive Impairment
NCT05495087
Recruiting
This phase I clinical trial will examine the safety and efficacy of intermittent hypoxia training (IHT) for up to 12 weeks to treat subjects with mild cognitive impairment (MCI).
Gender:
ALL
Ages:
Between 55 years and 80 years
Trial Updated:
04/03/2023
Locations: University of North Texas Health Science Center, Fort Worth, Texas
Conditions: Mild Cognitive Impairment, Memory Impairment
Register for Updates
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05503355
Recruiting
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: AML, Adult
Register for Updates
Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
NCT05204862
Recruiting
This study consists of Part A for monotherapy and Part B for combination therapy to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2 dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity of TU2218 at RP2D.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2023
Locations: NEXT Oncology, San Antonio, Texas
Conditions: Advanced Solid Tumor
Register for Updates
HR-EGG in Medically Refractory Gastroparesis
NCT05789511
Recruiting
The goal of this observational study is to utilize a novel high resolution electrogastrography device to gauge if identification of gastric dysarrythmias can reliably identify patients that will respond to or will require definitive pyloric interventions such as a G-POEM procedure in patients with medically refractory gastroparesis Aims: 1. Assess for the presence of gastric dysarrythmias in lung transplantation population as compared to alternative etiologies of gastroparesis 2. Assess if pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Gastroparesis, Lung Transplant; Complications
Register for Updates
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT05054296
Recruiting
This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with prostate cancer that has spread to other places in the body (metastatic) or has come back (recurrent) and does not response to treatment (refractory) and are receiving androgen deprivation therapy. Balancing treatment efficacy, drug side effects, and competing comorbidities with prostate cancer is essential. This trial is... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/28/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Children's Medical Center Dallas, UT Southwestern, Dallas, Texas
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma
NCT03787602
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Merkel Cell Carcinoma (MCC) who have failed treatment with at least one anti-PD-1 or anti-PD-L1 immunotherapy or in combination with avelumab in MCC patients who are anti-PD-1 or anti-PD-L1 treatment naïve. Inhibition of MDM2 is a novel mechanism of action in MCC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2023
Locations: University of Texas MD Anderson, Houston, Texas
Conditions: Merkel Cell Carcinoma
Register for Updates
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Register for Updates
Artificial Intelligence (AI) Cytopathology Trial
NCT05018663
Recruiting
Purpose The primary objective of the study is to compare interpretation of EUS FNA/FNB samples for adequacy between ROSE and AI at bedside. To compare accuracy of preliminary diagnosis results between ROSE and AI at bedside versus final pathology report. Research design This is a prospective single center study to compare performance characteristics in the interpretation of EUS FNA/FNB samples between AI and ROSE. Procedures to be used Eligible patients will undergo EUS guided FNA/FNA of PSLs... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/15/2023
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Pancreatic Solid Lesions
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
NCT05736029
Recruiting
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients. The investigators are going to search for correlation between specific biological features and response to immunotherapy, and to use those associations for developing an algorithm enabling to identify patients that could benefit from the immune check inhibitor based anti cancer treatment. Patients will provide biological samples before and during their treatment,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2023
Locations: Baylor Scott and White Research Institute, Dallas, Texas
Conditions: Non Small Cell Lung Cancer, Healthy
Register for Updates